PRELIMINARY RESULTS OF ASTX660, a NOVEL NON-PEPTIDOMIMETIC cIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T-Cell LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA

Hematological Oncology - United Kingdom
doi 10.1002/hon.211_2631
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (Aitl) and Cxcl12+ Peripheral T-Cell Lymphoma (Ptcl): Preliminary Results From a Phase 2 Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Outcome of Patients With Relapsed and Refractory Peripheral T Cell Lymphoma Intended for Stem Cell Transplant

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Angioimmunoblastic T-Cell Lymphoma: A Rare Subtype of Peripheral T-Cell Lymphoma

Clinical Case Reports
Medicine
2018English

Forodesine in the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma: An Evidence-Based Review

OncoTargets and Therapy
OncologyPharmacology
2018English

Cutaneous T Cell Lymphoma (Mycosis Fungoides)

JMS SKIMS
2010English

Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

Medical Journal Armed Forces India
Medicine
2007English

Nodal Peripheral T-Cell Lymphoma With Secondary Granulomatous Cutaneous Involvement

Acta Dermato-Venereologica
DermatologyMedicine
2004English

Peripheral T-Cell Lymphoma Mimicking Marginal Zone B-Cell Lymphoma

Modern Pathology
Forensic MedicinePathology
2002English

Cd20-TCB (Rg6026), a Novel “2:1” Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy